Christopher Paluch

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Realizing the potential of agonistic antibody immunotherapy.

Realizing the potential of agonistic antibody immunotherapy.

Journal: Nature reviews. Drug discovery
Published: April 13, 2026

A map of intra- and intercellular immune responses across diverse in vitro stimuli and inflammatory disease.

A map of intra- and intercellular immune responses across diverse in vitro stimuli and inflammatory disease.

Journal: Genome medicine
Published: August 20, 2025

Single-cell transcriptomic analysis of retinal immune regulation and blood-retinal barrier function during experimental autoimmune uveitis.

Single-cell transcriptomic analysis of retinal immune regulation and blood-retinal barrier function during experimental autoimmune uveitis.

Journal: Scientific reports
Published: August 31, 2023

Combination CD200R/PD-1 blockade in a humanised mouse model.

Combination CD200R/PD-1 blockade in a humanised mouse model.

Journal: Immunotherapy advances
Published: December 14, 2022

Antibody agonists trigger immune receptor signaling through local exclusion of receptor-type protein tyrosine phosphatases.

Antibody agonists trigger immune receptor signaling through local exclusion of receptor-type protein tyrosine phosphatases.

Journal: Immunity
Published: October 11, 2022

Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation.

Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation.

Journal: Nature immunology
Published: June 18, 2021

Immune Checkpoints as Therapeutic Targets in Autoimmunity.

Immune Checkpoints as Therapeutic Targets in Autoimmunity.

Journal: Frontiers in immunology
Published: June 08, 2018

Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity.

Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity.

Journal: Immunology
Published: November 24, 2016

Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation.

Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation.

Journal: Oncotarget
Published: March 09, 2016
Showing 1-9 of 9

Last Updated: 09/26/2026